Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb has secured approval from the European Commission for Opdivo (nivolumab) to treat adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
Subscribe to our email newsletter
Opdivo is now the first and only programmed death-1 (PD-1) inhibitor approved for a hematologic malignancy in the European Union (EU).
It is the company’s second immuno-oncology agent approved for a blood cancer in the EU within just six months. It is also the sixth EU approval for Opdivo in four different cancer types in less than two years.
Data from the phase 2 CheckMate -205 and the phase 1 CheckMate -039 trials served as the basis for the EC approval.
The trials assessed patients with relapsed or refractory cHL after ASCT and treatment with brentuximab vedotin.
In the subset of patients in the efficacy population (n=95), the primary endpoint of objective response rate (ORR) as assessed by an independent radiologic review committee was 66%.
The percentage of patients with a complete response was 6%, and the percentage of patients with a partial response was 60%. The progression-free survival rate was 57% at 12 months.
Opdivo is designed to harness the body’s own immune system to help restore anti-tumor immune response.
Its worldwide development program includes a range of clinical trials across all phases, including phase 3, in several tumor types.
More than 25,000 patients have so far been enrolled in the Opdivo clinical development program.
Opdivo is currently approved in over 57 countries, including the US, the EU and Japan.
Image: Bristol-Myers Squibb’s facility in Brussels, Belgium. Photo: courtesy of Bristol-Myers Squibb Company.